Liver Injury with Nintedanib: A Pharmacovigilance–Pharmacokinetic Appraisal

Drug-induced liver injury (DILI) with nintedanib has emerged as an adverse event of special interest in premarketing clinical trials. We characterized DILI with nintedanib in the real world and explored the underlying pharmacological basis. First, we assessed serious hepatic events reported to the F...

Descripción completa

Detalles Bibliográficos
Autores principales: Raschi, Emanuel, Fusaroli, Michele, Gatti, Milo, Caraceni, Paolo, Poluzzi, Elisabetta, De Ponti, Fabrizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146184/
https://www.ncbi.nlm.nih.gov/pubmed/35631471
http://dx.doi.org/10.3390/ph15050645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146184/
https://www.ncbi.nlm.nih.gov/pubmed/35631471
http://dx.doi.org/10.3390/ph15050645

Ejemplares similares